» Articles » PMID: 36012588

The Features of Immune Checkpoint Gene Regulation by MicroRNA in Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 26
PMID 36012588
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, the search for new promising tools of immunotherapy continues. In this regard, microRNAs (miRNAs) that influence immune checkpoint (IC) gene expression in tumor and T-cells and may be important regulators of immune cells are considered. MiRNAs regulate gene expression by blocking mRNA translation. An important feature of miRNA is its ability to affect the expression of several genes simultaneously, which corresponds to the trend toward the use of combination therapy. The article provides a list of miRNAs acting simultaneously on several ICs and miRNAs that, in addition to IC, can regulate the expression of targeted therapy genes. There is dependence of miRNA interactions with IC genes on the type of cancer. The analysis of the accumulated data demonstrates that only about 14% (95% CI: 9.8-20.1%) of the studied miRNAs regulate the expression of specific IC in more than one type of cancer. That is, there is tumor specificity in the miRNA action on ICs. A number of miRNAs demonstrated high efficiency in vitro and in vivo. This indicates the potential of miRNAs as promising agents for cancer immunotherapy. Additional studies of the miRNA-gene interaction features and the search for an optimal miRNA mimic structure are necessary.

Citing Articles

The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications.

Merenstein A, Obeidat L, Zaravinos A, Bonavida B Cancers (Basel). 2025; 17(1.

PMID: 39796650 PMC: 11718991. DOI: 10.3390/cancers17010019.


Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.

Vaxevanis C, Bachmann M, Seliger B J Immunother Cancer. 2024; 12(8).

PMID: 39209767 PMC: 11367391. DOI: 10.1136/jitc-2024-009774.


Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.

Saeed R, Abdulrahman Z, Mohammad D Saudi J Biol Sci. 2024; 31(7):104027.

PMID: 38831894 PMC: 11145380. DOI: 10.1016/j.sjbs.2024.104027.


MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.

Zabeti Touchaei A, Vahidi S Cancer Cell Int. 2024; 24(1):102.

PMID: 38462628 PMC: 10926683. DOI: 10.1186/s12935-024-03293-6.


Identification and Validation of Key miRNAs for Colon Cancer Based on miRNA-Gene Integration Analysis.

Ji Y, Gu J, Zhang H, Xu H Int J Gen Med. 2023; 16:5703-5718.

PMID: 38077476 PMC: 10710248. DOI: 10.2147/IJGM.S440340.


References
1.
Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

2.
Nguyen H, Phung C, Tran T, Pham T, Pham L, Nguyen T . Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA. J Control Release. 2020; 329:524-537. DOI: 10.1016/j.jconrel.2020.09.034. View

3.
Wei S, Wang K, Huang X, Zhao Z, Zhao Z . LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019; 33:2058738419859699. PMC: 6595645. DOI: 10.1177/2058738419859699. View

4.
Guo W, Tan W, Liu S, Huang X, Lin J, Liang R . MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol. 2015; 36(11):9049-57. DOI: 10.1007/s13277-015-3644-3. View

5.
Jiang K, Zou H . microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1. Bioengineered. 2021; 13(1):917-929. PMC: 8805988. DOI: 10.1080/21655979.2021.2014617. View